Mazdutide's strong results will position it well against the competition, and the valuation gap will narrow. The oncology portfolio will continue to flourish from a sales and valuation perspective.
What is covered in the Full Insight:
Introduction and business description
Partnerships
The development of mazdutide and target market in China
Valuations and future perspectives
Recommendation and conclusion
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.